Molecular imaging firm Blue Earth Diagnostics has competed the first commercial production of its Axumin PET radiopharmaceutical in Italy.
Axumin (fluciclovine fluorine-18) is indicated for the detection and localization of prostate cancer in men suspected of having cancer recurrence based on elevated blood prostate-specific antigen (PSA) levels after primary curative treatment.
Axumin is commercially available in Italy, France, Norway, the Czech Republic, the Netherlands, Austria, and the U.K. Blue Earth plans to expand to other European countries soon. It is approved for use in all European Union members, as well as Iceland, Liechtenstein, and Norway.
